{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:10:03Z","timestamp":1756455003233,"version":"3.44.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The objective of this study is to compare the effectiveness of reference biologic medicines used in the treatment of rheumatoid arthritis (RA) specifically adalimumab, etanercept, and infliximab, with corresponding biosimilar medicines, based on an exploratory analysis of clinical data obtained in patients treated with these medicines in five hospitals in the region of Catalonia, Spain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>There is a consultation of the database of the Registry of Patients and Treatments of the Catalan Health Service: extraction of data from adult patients diagnosed with moderate and severe active RA and with active prescription of at least one biological drug (reference or biosimilar) or JAK inhibitor. To compare the effectiveness of each reference biologic with its biosimilar, differences in mean DAS28-ESR values before and after treatment were assessed for adalimumab and its biosimilar, etanercept and its biosimilar, and infliximab and its biosimilar.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study consisted of 643 patients. The most dispensed medicines were anti-TNFs, with 303 patients on treatment. Thirty-six percent of all patients were using biosimilars. No statistically significant differences were observed in any of the three comparisons between the reference biologic medicine and its biosimilar. These findings suggest that biosimilars have comparable effectiveness to reference biologics in reducing DAS28-ESR; in addition, they can provide substantial savings to public health systems.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A significant number of patients diagnosed with moderate to severe active RA were treated with biological medicines and receiving the available biosimilar treatments. Future research should be conducted to confirm comparable effectiveness found to their reference biologic medicines in this exploratory analysis.\n<jats:table-wrap>\n                <jats:table>\n                  <jats:tbody>\n                    <jats:tr>\n                      <jats:td colspan=\"2\">\n                        <jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>Biosimilar use: 36% of rheumatoid arthritis (RA) patients in Catalonia are treated with biosimilars, exceeding the 12% recommendation. This reflects growing acceptance of these alternatives.<\/jats:italic>\u2022 <jats:italic>Comparative effectiveness: Biosimilars of adalimumab, etanercept, and infliximab showed comparable therapeutic benefit to their reference biologics in reducing disease activity in active rheumatoid arthritis.<\/jats:italic>\u2022 <jats:italic>Real-world data: The study provides real-world data from five hospitals, making biosimilar medicines a viable choice for rheumatologists in routine rheumatoid arthritis management.<\/jats:italic>\n                      <\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody>\n                <\/jats:table>\n              <\/jats:table-wrap>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10067-025-07568-9","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T17:05:00Z","timestamp":1753376700000},"page":"3445-3458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biosimilars and reference biological medicines in the treatment of rheumatoid arthritis: a multicenter cross-sectional study in Catalonia, Spain"],"prefix":"10.1007","volume":"44","author":[{"given":"Joan","family":"Mas Marin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Molina-Olano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5944-9182","authenticated-orcid":false,"given":"Nuria Rudi","family":"Sola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Miserachs-Aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Montoliu Alc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9024-1072","authenticated-orcid":false,"given":"Jan T.","family":"De Pourcq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carles","family":"Qui\u00f1ones Ribas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7556-4298","authenticated-orcid":false,"given":"Laura","family":"Borr\u00e0s Trias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Fern\u00e1ndez-Ca\u00f1abate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Gonz\u00e1lez-Valdivieso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8670-7426","authenticated-orcid":false,"given":"Carlos","family":"Figueiredo-Escrib\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7051-7871","authenticated-orcid":false,"given":"Ren\u00e9","family":"Delgado-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2669-7006","authenticated-orcid":false,"given":"Antonio J.","family":"Braza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-1284","authenticated-orcid":false,"given":"Cecilia F.","family":"Lastra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4386-9315","authenticated-orcid":false,"given":"Eduardo L.","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3193-6285","authenticated-orcid":false,"given":"Pilar","family":"Modamio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"11","key":"7568_CR1","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.3390\/cells10113017","volume":"10","author":"A-L Mueller","year":"2021","unstructured":"Mueller A-L, Payandeh Z, Mohammadkhani N, Mubarak SMH, Zakeri A, Alagheband Bahrami A et al (2021) Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies. Cells 10(11):3017. https:\/\/doi.org\/10.3390\/cells10113017","journal-title":"Cells"},{"issue":"1","key":"7568_CR2","doi-asserted-by":"publisher","first-page":"10242","DOI":"10.1016\/j.autrev.2019.102421","volume":"19","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Matucci-Cerinic M, Szekanecz Z (2020) The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. Autoimmun Rev 19(1):102421. https:\/\/doi.org\/10.1016\/j.autrev.2019.102421","journal-title":"Autoimmun Rev"},{"key":"7568_CR3","doi-asserted-by":"publisher","first-page":"790122","DOI":"10.3389\/fimmu.2021.790122","volume":"12","author":"J Zhao","year":"2021","unstructured":"Zhao J, Guo S, Schrodi SJ, He D (2021) Molecular and cellular heterogeneity in rheumatoid arthritis: mechanisms and clinical implications. Front Immunol 12:790122. https:\/\/doi.org\/10.3389\/fimmu.2021.790122","journal-title":"Front Immunol"},{"issue":"3","key":"7568_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.55563\/clinexprheumatol\/l9lyen","volume":"40","author":"F Petrelli","year":"2022","unstructured":"Petrelli F, Mariani FM, Alunno A, Puxeddu I (2022) Pathogenesis of rheumatoid arthritis: one year in review 2022. Clin Exp Rheumatol 40(3):475\u2013482. https:\/\/doi.org\/10.55563\/clinexprheumatol\/l9lyen","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"7568_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/acr2.11300","volume":"3","author":"S Yaacoub","year":"2021","unstructured":"Yaacoub S, Khamis AM, Al-Gibbawi M, Kahale LA, Bathon J, England BR et al (2021) Using parallel streams of evidence to inform guideline development: the case of the 2021 American College of Rheumatology management of rheumatoid arthritis guideline. ACR Open Rheumatol 3(9):629\u2013635. https:\/\/doi.org\/10.1002\/acr2.11300","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"7568_CR6","doi-asserted-by":"publisher","first-page":"e000900","DOI":"10.1136\/rmdopen-2019-000900","volume":"5","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY (2019) Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open 5(1):e000900. https:\/\/doi.org\/10.1136\/rmdopen-2019-000900","journal-title":"RMD Open"},{"issue":"3","key":"7568_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00296-019-04248-1","volume":"39","author":"DP Misra","year":"2019","unstructured":"Misra DP, Agarwal V (2019) Real-world evidence in rheumatic diseases: relevance and lessons learnt. Rheumatol Int 39(3):403\u2013416. https:\/\/doi.org\/10.1007\/s00296-019-04248-1","journal-title":"Rheumatol Int"},{"issue":"1","key":"7568_CR8","doi-asserted-by":"publisher","first-page":"21551","DOI":"10.1038\/s41598-020-76511-6","volume":"10","author":"L Silva-Fern\u00e1ndez","year":"2020","unstructured":"Silva-Fern\u00e1ndez L, Mac\u00eda-Villa C, Seoane-Mato D, Cort\u00e9s-Verd\u00fa R, Romero-P\u00e9rez A, Quevedo-Vila V et al (2020) The prevalence of rheumatoid arthritis in Spain. Sci Rep 10(1):21551. https:\/\/doi.org\/10.1038\/s41598-020-76511-6","journal-title":"Sci Rep"},{"key":"7568_CR9","doi-asserted-by":"publisher","first-page":"e004422","DOI":"10.1136\/rmdopen-2024-004422","volume":"10","author":"N Mena-V\u00e1zquez","year":"2024","unstructured":"Mena-V\u00e1zquez N, Ortiz-M\u00e1rquez F, Ram\u00edrez-Garc\u00eda T, Cabezudo-Garc\u00eda P, Garc\u00eda-Studer A, Mucientes-Ruiz A, Lisbona-Monta\u00f1ez JM, Borreg\u00f3n-Garrido P, Ruiz-Lim\u00f3n P, Redondo-Rodr\u00edguez R, Manrique-Arija S, Cano-Garc\u00eda L, Serrano-Castro PJ, Fern\u00e1ndez-Nebro A (2024) Impact of inflammation on cognitive function in patients with highly inflammatory rheumatoid arthritis. RMD Open 10:e004422. https:\/\/doi.org\/10.1136\/rmdopen-2024-004422","journal-title":"RMD Open"},{"key":"7568_CR10","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/cells10112857","volume":"10","author":"A-F Radu","year":"2021","unstructured":"Radu A-F, Bungau SG (2021) Management of rheumatoid arthritis: an overview. Cells 10:2857. https:\/\/doi.org\/10.3390\/cells10112857","journal-title":"Cells"},{"issue":"13","key":"7568_CR11","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360\u20131372. https:\/\/doi.org\/10.1001\/jama.2018.13103","journal-title":"JAMA"},{"key":"7568_CR12","unstructured":"Catalan Health Service. Departament of Health. Generalitat de Catalunya. Opinion of the Pharmacotherapeutic Committee of Hospital Outpatient Medicine on the use of adalimumab, abatacep, anakinra, certolizumab pegol, etanercept, golimumab, infliximab and tocilizumab in the treatment of rheumatoid arthritis in adult patients when the response to disease-modifying antirheumatic drugs (FAMMs) including methotrexate (MTX) has been inadequate. [In Catalan] 2013 [cited 2025\u201306\u201321]. Available from: https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/abatacept\/dictamen-artritis-reumatoide.pdf"},{"issue":"1","key":"7568_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41540-024-00454-1","volume":"10","author":"D Bedathuru","year":"2024","unstructured":"Bedathuru D, Rengaswamy M, Channavazzala M, Ray T, Packrisamy P, Kumar R (2024) Multiscale, mechanistic model of rheumatoid arthritis to enable decision making in late stage drug development. NPJ Syst Biol Appl 10(1):126. https:\/\/doi.org\/10.1038\/s41540-024-00454-1","journal-title":"NPJ Syst Biol Appl"},{"key":"7568_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12325-021-01944-y","volume":"39","author":"W Reinisch","year":"2022","unstructured":"Reinisch W, Cohen S, Ramchandani M, Khraishi M, Liu J, Chow V, Franklin J, Colombel JF (2022) A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar. Adv Ther 39:44\u201357. https:\/\/doi.org\/10.1007\/s12325-021-01944-y","journal-title":"Adv Ther"},{"issue":"4","key":"7568_CR15","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s11096-020-01200-3","volume":"43","author":"V Mart\u00ednez-Santana","year":"2021","unstructured":"Mart\u00ednez-Santana V, Boix-Monta\u00f1\u00e9s A, Fern\u00e1ndez-Ca\u00f1abate E, Gonz\u00e1lez-Melarde B, Miserachs-Aranda N, Modamio-Charles P, Fern\u00e1ndez-Lastra C, Mari\u00f1o-Hern\u00e1ndez E (2021) Remote pharmaceutical care for patients with rheumatoid arthritis and psoriasis. Int J Clin Pharm 43(4):938\u2013947. https:\/\/doi.org\/10.1007\/s11096-020-01200-3","journal-title":"Int J Clin Pharm"},{"key":"7568_CR16","doi-asserted-by":"publisher","unstructured":"\u00d8stergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordstr\u00f6m DC, Nurmohamed MT, Gudbjornsson B, \u00d8rnbjerg LM, B\u00f8yesen P, Lend K, H\u00f8rslev-Petersen K, Uhlig T, Sokka T, Grondal G, Krabbe S, Lindqvist J, Gjertsson I, Glinatsi D, Kapetanovic MC, Aga AB, Faustini F, Parmanne P, Lorenzen T, Giovanni C, Back J, Hendricks O, Vedder D, Rannio T, Grenholm E, Ljos\u00e5 MK, Brodin E, Lindegaard H, S\u00f6derbergh A, Rizk M, Kastbom A, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Bay Laurbjerg T, Bakland G, Olsen IC, Haavardsholm EA, Lampa J; NORD-STAR study group. (2023). Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis. 82(10):1286\u20131295. https:\/\/doi.org\/10.1136\/ard-2023-224116.","DOI":"10.1136\/ard-2023-224116"},{"issue":"12","key":"7568_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11926-018-0799-0","volume":"20","author":"L Chadwick","year":"2018","unstructured":"Chadwick L, Zhao S, Mysler E, Moots RJ (2018) Review of biosimilar trials and data on etanercept in rheumatoid arthritis. Curr Rheumatol Rep 20(12):84. https:\/\/doi.org\/10.1007\/s11926-018-0799-0","journal-title":"Curr Rheumatol Rep"},{"key":"7568_CR18","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair HA, Deeks ED (2017) Abatacept: A review in rheumatoid arthritis. Drugs 77:1221\u20131233. https:\/\/doi.org\/10.1007\/s40265-017-0775-4","journal-title":"Drugs"},{"key":"7568_CR19","unstructured":"Catalan Health Service. Departament of Health. Generalitat de Catalunya. (2018). Pharmacotherapeutic Commission for the Integrated Public Health System of Catalonia. CatSalut CFT-SISCAT agreement on the use of sarilumab in the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs, including methotrexate, has been inadequate. [In Catalan] [cited 2025\u201306\u201320]. Available from: https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/sarilumab-AR\/acord_CFT-SISCAT_Sarilumab_AR.pdf"},{"issue":"8","key":"7568_CR20","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1097\/RHU.0000000000001293","volume":"27","author":"RML Yip","year":"2021","unstructured":"Yip RML, Yim CW (2021) Role of interleukin 6 inhibitors in the management of rheumatoid arthritis. J Clin Rheumatol 27(8):e516\u2013e524. https:\/\/doi.org\/10.1097\/RHU.0000000000001293","journal-title":"J Clin Rheumatol"},{"issue":"7","key":"7568_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/14740338.2018.1486819","volume":"17","author":"J Ram\u00edrez","year":"2018","unstructured":"Ram\u00edrez J, Ca\u00f1ete JD (2018) Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf 17(7):727\u2013732. https:\/\/doi.org\/10.1080\/14740338.2018.1486819","journal-title":"Expert Opin Drug Saf"},{"key":"7568_CR22","unstructured":"Catalan Health Service. Departament of Health. Generalitat de Catalunya. (2018). Pharmacotherapeutic Commission for the Integrated Public Health System of Catalonia (CatSalut CFT-SISCAT) agreement on the use of baricitinib and tofacitinib in the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs, including methotrexate, has been inadequate. [In Catalan], [cited 2025\u201306\u201320]. Available from: https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/_compartits\/AvaluacioArtritisReumatoide\/Acord_CFT-SISCAT_Baricitinib_Tofacitinib_AR.pdf"},{"issue":"18","key":"7568_CR23","doi-asserted-by":"publisher","first-page":"6632","DOI":"10.3390\/ijms21186632","volume":"21","author":"J Amrhein","year":"2020","unstructured":"Amrhein J, Drynda S, Schlatt L, Karst U, Lohmann CH, Ciarimboli G, Bertrand J (2020) Tofacitinib and baricitinib are taken up by different uptake mechanisms determining the efficacy of both drugs in RA. Int J Mol Sci 21(18):6632. https:\/\/doi.org\/10.3390\/ijms21186632","journal-title":"Int J Mol Sci"},{"issue":"8","key":"7568_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.reumae.2024.09.002","volume":"20","author":"JM \u00c1lvaro-Gracia \u00c1lvaro","year":"2024","unstructured":"\u00c1lvaro-Gracia \u00c1lvaro JM, Del Campo D, Fontecha P, Andr\u00e9u S\u00e1nchez JL, Balsa Criado A, C\u00e1liz C\u00e1liz R, Castrej\u00f3n Fern\u00e1ndez I, Corominas H, G\u00f3mez Puerta JA, Manrique Arija S, Mena V\u00e1zquez N, Ortiz Garc\u00eda A, Plasencia Rodr\u00edguez C, Silva Fern\u00e1ndez L, Tornero MJ (2024) Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis. Reumatol Clin (Engl Ed) 20(8):423\u2013439. https:\/\/doi.org\/10.1016\/j.reumae.2024.09.002","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"7568_CR25","doi-asserted-by":"publisher","unstructured":"Balsa A, D\u00edaz Del Campo Fontecha P, Silva Fern\u00e1ndez L, Valencia Mart\u00edn J, Nistal Mart\u00ednez V, Le\u00f3n V\u00e1zquez F, et al. (2023). Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis. Reumatol Clin (Engl Ed) 19(10):533\u2013548. https:\/\/doi.org\/10.1016\/j.reumae.2023.07.004","DOI":"10.1016\/j.reumae.2023.07.004"},{"issue":"5","key":"7568_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/annrheumdis-2019-216607","volume":"79","author":"S Takanashi","year":"2020","unstructured":"Takanashi S, Kaneko Y, Takeuchi T (2020) CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice. Ann Rheum Dis 79(5):671\u2013674. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216607","journal-title":"Ann Rheum Dis"},{"key":"7568_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fmed.2018.00185","volume":"5","author":"CK Orr","year":"2018","unstructured":"Orr CK, Najm A, Young F, McGarry T, Biniecka M, Fearon U, Veale DJ (2018) The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis. Front Med (Lausanne) 5:185. https:\/\/doi.org\/10.3389\/fmed.2018.00185","journal-title":"Front Med (Lausanne)"},{"key":"7568_CR28","unstructured":"Catalan Health Service. Departament of Health. Generalitat de Catalunya. (2021). Programa d\u2019Harmonitzaci\u00f3 Farmacoterap\u00e8utica. Tractament de l\u2019artritis reumatoide activa de moderada a greu quan la resposta als FAMM ha estat inadequada: informe d\u2019avaluaci\u00f3 de resultats. chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/scientiasalut.gencat.cat\/bitstream\/handle\/11351\/6671\/tractament_artritis_reumatoide_activa_moderada_greu_quan_resposta_FAMM_inadequada_%20informe_avaluacio_resultats_2021.pdf?sequence=1&isAllowed=y"},{"key":"7568_CR29","unstructured":"Garc\u00eda Martin E, De la Cruz Murie P, Ibarra Barrueta MO, Serrano Gim\u00e9nez R, Monte Boquet E, Borr\u00e1s Blasco J et al (2020) Guide to pharmaceutical practice in rheumatoid arthritis. SEFH (Spanish Society of Hospital Pharmacy) [In Spanish]. Available from: https:\/\/www.sefh.es\/bibliotecavirtual\/reuma2\/GuiadePracticaFarmaceuticaenArtritisReumatoide.pdf?ts=20210219132646. Accessed 20 June 2025"},{"key":"7568_CR30","unstructured":"Catalan Health Service. Departament of Health. Generalitat de Catalunya (2013) Pharmacotherapeutic committee of the hospital outpatient dispensing medicine. Opinion of the pharmacotherapeutic committee of the hospital outpatient medicine on the use of adalimumab, abatacept, anakinra, certolizumab pegol, etanercept, golimumab, infliximab and tocilizumab for the treatment of rheumatoid arthritis [In Catalan]. [cited 2025\u201306\u201320]. Available from: https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/abatacept\/dictamen-artritis-reumatoide.pdf"},{"key":"7568_CR31","unstructured":"Catalan Health Service. Departament of Health. Generalitat de Catalunya (2017) Pharmacoterapeutic Harmonization Program. [In Catalan]. Available from: https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/normativa\/instruccio-05-2017-programa-harmonitzacio-farmacoterapeutica.pdf. Accessed 20 Jun 2025"},{"key":"7568_CR32","unstructured":"Troein P, Newton M, Scott K. (2020). The impact of biosimilar competition in Europe. IQVIA.:2\u20133. [cited 2025\u201306\u201320]. Available from: https:\/\/www.iqvia.com\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe"},{"key":"7568_CR33","unstructured":"Spanish Society of Hospital Pharmacy. (2018). Position paper of the Spanish Society of Hospital Pharmacy on biosimilar medicines. [In Spanish]. [cited 2025\u201306\u201320]. Available from: https:\/\/www.sefh.es\/sefhpdfs\/PosicionamientoBiosimilaresSEFH_documentocompleto_Definitivo.pdf"},{"key":"7568_CR34","unstructured":"Servei Catal\u00e0 la Salut Ger\u00e8ncia del Medicament. The Outpatient Hospital Medication Prescription Quality Index (IQF-MDA). (2019); Versi\u00f3 201 (Barcelona)."},{"issue":"4","key":"7568_CR35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jbspin.2019.01.001","volume":"86","author":"L Frantzen","year":"2019","unstructured":"Frantzen L, Cohen JD, Trop\u00e9 S, Beck M, Munos A, Sittler MA et al (2019) Patients\u2019 information and perspectives on biosimilars in rheumatology: a French nation-wide survey. Joint Bone Spine 86(4):491\u2013496. https:\/\/doi.org\/10.1016\/j.jbspin.2019.01.001","journal-title":"Joint Bone Spine"},{"issue":"3","key":"7568_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40259-021-00479-6","volume":"35","author":"AR Kolbe","year":"2021","unstructured":"Kolbe AR, Kearsley A, Merchant L, Temkin E, Patel A, Xu J et al (2021) Physician understanding and willingness to prescribe biosimilars: findings from a US National Survey. BioDrugs 35(3):363\u2013372. https:\/\/doi.org\/10.1007\/s40259-021-00479-6","journal-title":"BioDrugs"},{"issue":"4","key":"7568_CR37","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.xphs.2021.02.003","volume":"110","author":"J Coghlan","year":"2021","unstructured":"Coghlan J, He H, Schwendeman AS (2021) Overview of Humira\u00ae Biosimilars: current European landscape and future implications. J Pharm Sci 110(4):1572\u20131582. https:\/\/doi.org\/10.1016\/j.xphs.2021.02.003","journal-title":"J Pharm Sci"},{"issue":"1","key":"7568_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10067-020-05199-w","volume":"40","author":"C Bruni","year":"2021","unstructured":"Bruni C, Bitti R, Nacci F, Cometi L, Tofani L, Bartoli F et al (2021) Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases. Clin Rheumatol 40(1):85\u201391. https:\/\/doi.org\/10.1007\/s10067-020-05199-w","journal-title":"Clin Rheumatol"},{"key":"7568_CR39","doi-asserted-by":"publisher","unstructured":"Delgado S\u00e1nchez O, Ginard Vicens D, Sampol Mayol A, Terrasa Pons J. (2019). Biosimilar medicines: impact, opportunities and strategies. Twelve years of experience in Europe. Med Clin (Barc).152(10):411\u20135. https:\/\/doi.org\/10.1016\/j.medcli.2018.11.013.","DOI":"10.1016\/j.medcli.2018.11.013"},{"key":"7568_CR40","unstructured":"European Medicine Agency. (2023). Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU [In English] [cited 2025\u201306\u201320]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf"},{"key":"7568_CR41","doi-asserted-by":"publisher","unstructured":"Cooksey R, Brophy S, Kennedy J, Seaborne M, Choy E. (2022). Real-world use of an etanercept biosimilar including selective versus automatic substitution in inflammatory arthritis patients: a UK-based electronic health records study. Rheumatol Adv Pract. 6(2):rkac056. https:\/\/doi.org\/10.1093\/rap\/rkac056.","DOI":"10.1093\/rap\/rkac056"},{"issue":"Suppl 1","key":"7568_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.31138\/mjr.30.1.69","volume":"30","author":"AV Madenidou","year":"2019","unstructured":"Madenidou AV, Jeffries A, Varughese S, Jones S, Sari-Kouzel H, Veevers H, Rao C (2019) Switching patients with inflammatory arthritis from Etanercept (Enbrel\u00ae) to the biosimilar drug, SB4 (Benepali\u00ae): a single-centre retrospective observational study in the UK and a review of the literature. Mediterr J Rheumatol 30(Suppl 1):69\u201375. https:\/\/doi.org\/10.31138\/mjr.30.1.69","journal-title":"Mediterr J Rheumatol"},{"key":"7568_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/ard-2023-224477","volume":"83","author":"V Konzett","year":"2024","unstructured":"Konzett V, Kerschbaumer A, Smolen JS, Aletaha D (2024) Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis. Ann Rheum Dis 83:58\u201364. https:\/\/doi.org\/10.1136\/ard-2023-224477","journal-title":"Ann Rheum Dis"},{"key":"7568_CR44","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-Franco RM, G\u00f3mez-G\u00f3mez D, Valero-Dom\u00ednguez M. (2024). Introduction of anti-TNF biosimilars and economic impact in a tertiary care hospital (Spanish). Rev. OFIL\u00b7ILAPHAR 33(2). https:\/\/doi.org\/10.4321\/s1699-714x2023000200007","DOI":"10.4321\/s1699-714x2023000200007"},{"key":"7568_CR45","unstructured":"G\u00f3mez-G\u00f3mez D, Col\u00f3n L\u00f3pez De Dicastillo A, Ochagav\u00eda Sufrategui M, Valero Dom\u00ednguez M (2015). Estimation of the real cost of anti-TNF therapies in rheumatic diseases (Spanish). Rev. O.F.I.L. 25(2):91\u2013100. https:\/\/www.ilaphar.org\/estimacion-del-coste-real-de-las-terapias-anti-tnf-en-enfermedades-reumaticas\/"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07568-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07568-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07568-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:50:01Z","timestamp":1756453801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07568-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7568"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07568-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was approved by the research committee of the Hospital General de Granollers (Granollers, Barcelona, Spain) (code number 20204002) in March 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}